Texas Permanent School Fund boosted its stake in shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) by 4.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 22,600 shares of the specialty pharmaceutical company’s stock after acquiring an additional 909 shares during the quarter. Texas Permanent School Fund owned about 0.07% of AMAG Pharmaceuticals worth $343,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors also recently bought and sold shares of AMAG. Prudential Financial Inc. boosted its stake in AMAG Pharmaceuticals by 18.4% in the 3rd quarter. Prudential Financial Inc. now owns 190,336 shares of the specialty pharmaceutical company’s stock worth $3,807,000 after purchasing an additional 29,612 shares in the last quarter. AXA lifted its stake in AMAG Pharmaceuticals by 217.3% during the 3rd quarter. AXA now owns 93,600 shares of the specialty pharmaceutical company’s stock valued at $1,872,000 after acquiring an additional 64,100 shares during the period. Martingale Asset Management L P bought a new position in AMAG Pharmaceuticals during the 3rd quarter valued at about $309,000. Trexquant Investment LP bought a new position in AMAG Pharmaceuticals during the 3rd quarter valued at about $416,000. Finally, Panagora Asset Management Inc. lifted its stake in AMAG Pharmaceuticals by 11.0% during the 3rd quarter. Panagora Asset Management Inc. now owns 220,158 shares of the specialty pharmaceutical company’s stock valued at $4,403,000 after acquiring an additional 21,748 shares during the period.
AMAG has been the subject of several research reports. ValuEngine lowered shares of AMAG Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Friday, February 15th. B. Riley set a $21.00 price target on AMAG Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, January 16th. Zacks Investment Research raised AMAG Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, January 23rd. SunTrust Banks began coverage on AMAG Pharmaceuticals in a report on Tuesday, March 19th. They issued a “hold” rating for the company. Finally, Cantor Fitzgerald restated a “hold” rating and set a $14.00 price target (down previously from $17.00) on shares of AMAG Pharmaceuticals in a report on Thursday, March 14th. Three analysts have rated the stock with a sell rating, eight have given a hold rating and one has given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $20.21.
AMAG Pharmaceuticals (NASDAQ:AMAG) last issued its quarterly earnings results on Thursday, February 7th. The specialty pharmaceutical company reported ($0.60) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.98) by $0.38. AMAG Pharmaceuticals had a negative net margin of 13.07% and a negative return on equity of 17.10%. The company had revenue of $88.10 million during the quarter, compared to the consensus estimate of $95.21 million. During the same quarter in the prior year, the firm posted $0.10 EPS. The firm’s quarterly revenue was down 31.4% on a year-over-year basis. As a group, sell-side analysts predict that AMAG Pharmaceuticals, Inc. will post -3.2 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://www.baseballdailydigest.com/news/2019/04/15/texas-permanent-school-fund-buys-909-shares-of-amag-pharmaceuticals-inc-amag.html.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.
Featured Story: How accurate is the Rule of 72?
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.